Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enoblituzumab (Primary) ; Ipilimumab
Indications Breast cancer; Colon cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
Focus Adverse reactions
Sponsors MacroGenics

Most Recent Events

21 Mar 2019 Status changed from active, no longer recruiting to completed.
07 May 2018 According to a MacroGenics media release, the company expects to present clinical data from this study in the second half of 2018.
02 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com